StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Free Report) in a research report report published on Saturday. The firm issued a hold rating on the stock.
TherapeuticsMD Stock Performance
TXMD stock opened at $1.95 on Friday. The firm’s 50-day moving average is $2.29 and its two-hundred day moving average is $2.35. TherapeuticsMD has a 52 week low of $1.95 and a 52 week high of $4.73.
Hedge Funds Weigh In On TherapeuticsMD
Hedge funds have recently modified their holdings of the company. Millennium Management LLC raised its position in TherapeuticsMD by 339.2% in the second quarter. Millennium Management LLC now owns 57,657 shares of the company’s stock worth $574,000 after acquiring an additional 44,528 shares in the last quarter. BlackRock Inc. increased its stake in TherapeuticsMD by 18.1% in the 2nd quarter. BlackRock Inc. now owns 137,127 shares of the company’s stock worth $565,000 after purchasing an additional 20,995 shares in the last quarter. Geode Capital Management LLC purchased a new stake in shares of TherapeuticsMD in the 4th quarter valued at approximately $374,000. Royal Bank of Canada lifted its stake in TherapeuticsMD by 688.1% in the 1st quarter. Royal Bank of Canada now owns 788,446 shares of the company’s stock worth $299,000 after acquiring an additional 688,399 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in TherapeuticsMD in the 4th quarter valued at approximately $249,000. 30.74% of the stock is currently owned by institutional investors and hedge funds.
About TherapeuticsMD
TherapeuticsMD, Inc operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors.
Read More
- Five stocks we like better than TherapeuticsMD
- 3 REITs to Buy and Hold for the Long Term
- The Charles Schwab Company Can Hit New Highs
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- How to Use the MarketBeat Stock Split Calculator
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
